Sanofi and Regeneron’s investigational IL-33 inhibitor faces a significant hurdle as inconsistent Phase III data places it at a disadvantage against a strong competitor.
The landscape of chronic obstructive pulmonary disease (COPD) treatment, a notoriously complex and debilitating condition, has been keenly watching the progress of itepekimab. Developed jointly by Sanofi and Regeneron, this fully human interleukin-33 (IL-33) monoclonal antibody (mAb) has shown promise in targeting the underlying inflammation associated with COPD. However, recent data presented at the 2026 American Thoracic Society (ATS) International Conference has cast a significant shadow over its potential in this indication, particularly when contrasted with the robust performance of a competing therapy.
The core of the concern lies in the divergent outcomes of the AERIFY-1 and AERIFY-2 Phase III clinical trials. While AERIFY-1 demonstrated statistically significant reductions in exacerbations, a key marker of disease progression and patient quality of life in COPD, AERIFY-2 failed to replicate these positive findings. This stark discrepancy, which remained largely unresolved by the newly presented data, raises serious questions about the drug’s consistent efficacy and presents a formidable challenge for its anticipated regulatory approval.
The AERIFY Trials: A Tale of Two Outcomes
Sanofi and Regeneron presented updated safety and efficacy data from their AERIFY-1 (NCT04701983) and AERIFY-2 (NCT04751487) trials on May 16, 2026, at the ATS International Conference. These pivotal studies were designed to evaluate the effectiveness of itepekimab in former smokers diagnosed with moderate to severe COPD. The trials enrolled patients with a substantial smoking history, defined as 10 or more pack-years. Notably, AERIFY-2 also included a small cohort of patients who were actively smoking at least one cigarette per day on average. Both studies investigated two different dosing regimens of itepekimab: 300mg administered every two weeks (q2w) and 300mg administered every four weeks (q4w). Patients in both trials were characterized by their high risk of exacerbations, a common and often severe complication of COPD.
The data revealed at the ATS conference focused specifically on the population of patients with a history of smoking, excluding current smokers, and mirrored the findings initially reported in 2024. In the AERIFY-1 trial, the results were encouraging. Patients receiving itepekimab experienced a statistically significant reduction in the annualized rate of moderate or severe exacerbations compared to placebo. The q2w dosing group saw a reduction of 27.1%, while the q4w group observed a 20.5% decrease. These figures suggested a meaningful impact on disease control and potentially a reduced burden on healthcare systems and patients.
However, the narrative dramatically shifted when examining the AERIFY-2 trial. In this study, the same patient population—former smokers with moderate to severe COPD—did not show the same level of benefit. The reductions in annualized exacerbation rates were markedly attenuated. The q4w dosing arm reported a reduction of only 12.4%, and the q2w arm showed a mere 1.6% decrease. Crucially, neither of these reductions reached statistical significance when compared to the placebo group. This failure of AERIFY-2 to corroborate the positive results of AERIFY-1 is the central issue that now clouds itepekimab’s future in COPD.
Chronology of Disappointment and Hope
The journey of itepekimab in COPD has been a rollercoaster of expectations and, now, considerable concern. The initial unveiling of data from the AERIFY trials in 2024 offered a glimmer of hope. At that time, it was announced that AERIFY-1 had met its primary endpoints by demonstrating a significant reduction in exacerbations. This was a crucial milestone, signaling potential efficacy for the novel IL-33 inhibitor.
However, the simultaneous announcement of the AERIFY-2 results revealed a less definitive picture. While it was acknowledged that AERIFY-2 had also been conducted, the lack of clear, statistically significant benefit in the same patient population was a notable omission from the initial positive pronouncements. This discrepancy immediately raised questions within the scientific and medical community about the drug’s overall reliability and the factors that might be contributing to the differing outcomes between two seemingly similar Phase III trials.
The data presented at ATS 2026 was intended to provide further clarity and potentially reconcile the conflicting results. The focus on a specific subgroup of patients (former smokers) aimed to narrow the scope and perhaps highlight a more consistent pattern. Yet, the updated findings confirmed the initial observations: AERIFY-1 continued to show benefit, while AERIFY-2 continued to fall short of statistical significance in the former smoker cohort. The new data did not offer a compelling explanation for this divergence, leaving the core problem unresolved and intensifying the challenges for Sanofi and Regeneron.
Supporting Data: A Closer Look at the Numbers
The statistical significance of clinical trial results is paramount, especially when seeking regulatory approval for new therapies. In the case of itepekimab, the disparity in statistical significance between AERIFY-1 and AERIFY-2 is the defining feature of its current development status in COPD.
AERIFY-1 (Former Smokers):
- Annualized Rate of Moderate/Severe Exacerbations vs. Placebo:
- 300mg q2w: 27.1% reduction (statistically significant)
- 300mg q4w: 20.5% reduction (statistically significant)
AERIFY-2 (Former Smokers):
- Annualized Rate of Moderate/Severe Exacerbations vs. Placebo:
- 300mg q2w: 1.6% reduction (not statistically significant)
- 300mg q4w: 12.4% reduction (not statistically significant)
These figures paint a clear picture: AERIFY-1 provides robust evidence of efficacy in reducing exacerbations for former smokers. AERIFY-2, on the other hand, offers at best a weak signal of potential benefit that does not meet the threshold for statistical confidence. This means that regulatory bodies, such as the US Food and Drug Administration (FDA), are unlikely to view the results of a single trial (AERIFY-1) as sufficient evidence for approval, especially when a similarly designed and conducted trial (AERIFY-2) failed to replicate those findings. The lack of replication is a critical red flag in drug development.
Beyond efficacy, the safety profile of itepekimab across both trials was generally favorable. Treatment-emergent adverse events were reported to be manageable, with severe events occurring in approximately 17-18% of patients in both AERIFY-1 and AERIFY-2, across both dosing regimens. This suggests that the drug is likely to be well-tolerated by patients, which is a positive aspect. However, a strong safety profile cannot compensate for a lack of consistent efficacy.
Official Responses and Strategic Implications
Sanofi and Regeneron have acknowledged the divergent results between the AERIFY trials. While they have not issued a formal statement specifically addressing the ATS 2026 presentation, their past communications have emphasized the overall commitment to developing itepekimab for respiratory diseases. The companies are likely to continue analyzing the data, seeking potential explanations for the discrepancy, and determining the best path forward. This could involve further subgroup analyses, exploring potential biomarkers, or even considering additional studies.
However, the immediate implication of these results is a significant setback for itepekimab’s prospects in the COPD market. The inconsistent efficacy data from the AERIFY-2 trial poses a substantial hurdle to obtaining FDA approval. Regulatory agencies typically require positive results from at least two well-controlled, independent trials to demonstrate the safety and efficacy of a new drug for a given indication. The failure of AERIFY-2 to meet this standard for COPD is a critical challenge.
The situation is further complicated by the emergence of a strong competitor. AstraZeneca has recently reported positive topline results for its own anti-IL-33 mAb, tozorakimab. In March 2026, AstraZeneca announced that tozorakimab had met its primary endpoints in both the OBERON (NCT05166889) and TITANIA (NCT05158387) Phase III trials for moderate to severe COPD. Crucially, tozorakimab demonstrated consistent and statistically significant reductions in exacerbation rates in both former smoking and current smoking patient populations. This consistent efficacy across two replicate trials and a broader patient demographic positions AstraZeneca favorably to establish tozorakimab as the leading anti-IL-33 agent in the COPD space. This leaves itepekimab with a significantly narrowed and more challenging path to market entry for this specific indication.
Broader Context and Future Outlook
Despite the disappointing news for itepekimab in COPD, Sanofi and Regeneron are not without significant commercial presence in the respiratory therapeutic area. Their blockbuster drug, Dupixent (dupilumab), received FDA and European Medicines Agency (EMA) approval for COPD in 2024. Dupixent is expected to remain a major growth driver for the companies in this indication until its eventual loss of market exclusivity. Therefore, the setback for itepekimab in COPD, while a pipeline disappointment, is unlikely to represent an existential commercial threat for either Sanofi or Regeneron.
The focus for itepekimab may now shift, or at least be re-prioritized, towards other indications where the role of IL-33 is more definitively established and where its efficacy may be less susceptible to trial-specific variability. One such area is chronic rhinosinusitis with nasal polyps (CRSwNP). Itepekimab remains a promising candidate for this condition, with a Phase III clinical trial (NCT06834347) currently actively recruiting patients. The well-established role of IL-33 in driving Type 2 airway inflammation, as highlighted in research by Song and colleagues in 2017, provides a strong scientific rationale for its potential benefit in CRSwNP.
In conclusion, the inconsistent performance of the AERIFY-2 trial has placed itepekimab on the backfoot in the highly competitive COPD market. The failure to replicate the positive results seen in AERIFY-1 casts doubt on its path to regulatory approval and positions AstraZeneca’s tozorakimab as a formidable contender in the anti-IL-33 space for COPD. While Sanofi and Regeneron possess other established respiratory assets, the COPD indication for itepekimab now faces a significantly more challenging and uncertain future. The company’s focus may increasingly turn towards other promising avenues for this investigational therapy, particularly in conditions where the underlying biology of IL-33 is more clearly understood and its therapeutic potential has been more consistently demonstrated.
About the Author
